Cahit Yilmaz, Can A. Karaca, Rasim Ferecov, Zaza Iakobadze, Kamil Kilic, Adnan Tosun, Murat Kilic – 6 November 2017

Elena Khanova, Raymond Wu, Wen Wang, Rui Yan, Yibu Chen, Samuel W. French, Cristina Llorente, Stephanie Q. Pan, Qihong Yang, Yuchang Li, Raul Lazaro, Charles Ansong, Richard D. Smith, Ramon Bataller, Timothy Morgan, Bernd Schnabl, Hidekazu Tsukamoto – 6 November 2017 – Alcoholic hepatitis (AH) continues to be a disease with high mortality and no efficacious medical treatment. Although severe AH is presented as acute on chronic liver failure, what underlies this transition from chronic alcoholic steatohepatitis (ASH) to AH is largely unknown.

Michael Patrick Johnston, Iona Campbell, Judith Morris, Fiona Finlay – 6 November 2017

Filipe S. Cardoso, Michelle Gottfried, Shannan Tujios, Jody C. Olson, Constantine J. Karvellas, For the US Acute Liver Failure Study Group – 6 November 2017

Elena Khanova, Raymond Wu, Wen Wang, Rui Yan, Yibu Chen, Samuel W. French, Cristina Llorente, Stephanie Q. Pan, Qihong Yang, Yuchang Li, Raul Lazaro, Charles Ansong, Richard D. Smith, Ramon Bataller, Timothy Morgan, Bernd Schnabl, Hidekazu Tsukamoto – 6 November 2017 – Alcoholic hepatitis (AH) continues to be a disease with high mortality and no efficacious medical treatment. Although severe AH is presented as acute on chronic liver failure, what underlies this transition from chronic alcoholic steatohepatitis (ASH) to AH is largely unknown.

Aditi Varshney, Jiban J. Panda, Avishek K. Singh, Nitin Yadav, Chhagan Bihari, Subhrajit Biswas, Shiv K. Sarin, Virander S. Chauhan – 6 November 2017 – Hepatocellular carcinoma (HCC) is an aggressive tumor with limited systemic and locoregional modalities of treatment. Although microRNA (miRNA) based therapies have significant potential, their targeted delivery remains a major challenge. miR‐199a‐3p functions as an important tumor suppressor in HCC, which regulates various cellular processes.

Chetan Kalal, Akash Shukla, Ravi Mohanka, Samir Shah – 6 November 2017

Kenneth E. Sherman, Marion G. Peters, David Thomas – 6 November 2017 – Among persons living with human immunodeficiency virus (HIV) infection, liver disease remains a major cause of morbidity and mortality. While the etiologies are varied and often overlapping in the individual patient, the underlying mechanisms, including oxidative stress, direct activation of stellate cells, HIV interaction with hepatocytes, and bacterial translocation with systemic immune activation, seem to be unifying characteristics.

Cameron Sikavi, Phillip H. Chen, Alex D. Lee, Elena G. Saab, Gina Choi, Sammy Saab – 6 November 2017 – The treatment of chronic hepatitis C (HCV) in human immunodeficiency virus 1 (HIV)–infected individuals has been historically marked by low sustained virologic response (SVR) rates in comparison to those without HIV infection, resulting in the Food and Drug Administration labeling those coinfected as a “special population with an unmet medical need.” We systematically reviewed the treatment of chronic HCV infection in those infected with HIV.

Cyrielle Caussy, Mosab H. Alquiraish, Phirum Nguyen, Carolyn Hernandez, Sandra Cepin, Lynda E. Fortney, Veeral Ajmera, Ricki Bettencourt, Summer Collier, Jonathan Hooker, Ethan Sy, Emily Rizo, Lisa Richards, Claude B. Sirlin, Rohit Loomba – 6 November 2017 – The optimal threshold of controlled attenuation parameter (CAP) for the detection of hepatic steatosis using both M and XL probe is unknown in nonalcoholic fatty liver disease (NAFLD).